In a Push to Limit Use of Glucocorticoids, US and EU5 Rheumatologists are Increasingly Turning to GSK’s Benlysta and AstraZeneca’s Saphnelo for the Treatment of Moderate-to-Severe Systemic Lupus Erythematosus, According to Spherix Global In Exton, Pennsylvania, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Prior to the initial approval of Benlysta in 2011, systemic lupus erythematosus (SLE) patients and prescribers had limited options for the...

Scipher Medicine Presents New Data at the European League Against Rheumatism (EULAR) 2021 Further Validating PrismRA® Test Molecular signature test predicts likelihood of non-response to adalimumab or etanercept, two of the world’s most expensive medications, in an independent validation cohort PrismRA demonstrates a more...

Corbus Pharmaceuticals Announces Presentation of Six Abstracts at EULAR 2019 Annual Meeting New data from ongoing Phase 2 open-label extension of lenabasum in systemic sclerosis and open-label extension data in dermatomyositis studies to be presentedPresentation includes data from some...

Epidemiologic Study Findings Show Over 400 Percent Increase in Gout Patient Hospitalizations Since 1993 MADRID, Spain, June 14, 2017 (GLOBE NEWSWIRE) -- Results from a new study to be presented tomorrow at the Annual European Congress of Rheumatology (EULAR) 2017 show a 410 percent increase in...

Prothena to Present Clinical Results From its Phase 1 Single Ascending Dose Study of PRX003, an Anti-MCAM Antibody Being Investigated for Inflammatory Diseases, at EULAR 2016 DUBLIN, Ireland, May 09, 2016 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of...